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EFFECTS OF THYROXINE AS COMPARED WITH THYROXINE PLUS 










































































Patients with hypothyroidism are usu-
ally treated with thyroxine (levothyroxine) only, al-
though both thyroxine and triiodothyronine are se-
creted by the normal thyroid gland. Whether thyroid





We compared the effects of thyroxine
alone with those of thyroxine plus triiodothyronine
(liothyronine) in 33 patients with hypothyroidism.
Each patient was studied for two five-week periods.
During one period, the patient received his or her
usual dose of thyroxine. During the other, the patient
received a regimen in which 50 µg of the usual dose
of thyroxine was replaced by 12.5 µg of triiodothyro-
nine. The order in which each patient received the
two treatments was randomized. Biochemical, phys-
iologic, and psychological tests were performed at




The patients had lower serum free and to-
tal thyroxine concentrations and higher serum total
triiodothyronine concentrations after treatment with
thyroxine plus triiodothyronine than after thyroxine
alone, whereas the serum thyrotropin concentrations
were similar after both treatments. Among 17 scores
on tests of cognitive performance and assessments
of mood, 6 were better or closer to normal after
treatment with thyroxine plus triiodothyronine. Sim-
ilarly, among 15 visual-analogue scales used to in-
dicate mood and physical status, the results for 10
were significantly better after treatment with thyrox-
ine plus triiodothyronine. The pulse rate and serum
sex hormone–binding globulin concentrations were
slightly higher after treatment with thyroxine plus tri-
iodothyronine, but blood pressure, serum lipid con-
centrations, and the results of neurophysiologic tests




In patients with hypothyroidism, par-
tial substitution of triiodothyronine for thyroxine may
improve mood and neuropsychological function; this
finding suggests a specific effect of the triiodothyro-
nine normally secreted by the thyroid gland. (N Engl
J Med 1999;340:424-9.)
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HERE are two thyroid hormones, thyroxine
and triiodothyronine. The daily produc-
tion of thyroxine is about 100 µg, all pro-
duced by the thyroid gland. The daily pro-
duction of triiodothyronine is about 30 µg, of which
about 20 percent is produced by the thyroid gland





 Not all tissues that need thyroid
T
 
hormone are equally able to convert thyroxine to tri-





ertheless, most patients with hypothyroidism are
treated only with thyroxine (levothyroxine). Although
this treatment is effective, some patients with hy-





 This observation, plus the existence of differ-
ences in the rate of conversion of thyroxine to tri-




 prompted us to
compare the effects of thyroxine alone with those of
thyroxine plus triiodothyronine (liothyronine) on
thyroid hormone actions in the brain, pituitary gland,






We invited patients with chronic autoimmune thyroiditis or
thyroid cancer treated by near-total thyroidectomy who received
care at the Institute of Endocrinology of Kaunas Medical Univer-
sity in Kaunas, Lithuania, to participate in the study if they were
totally, or nearly totally, dependent on exogenous thyroxine. The
patients with chronic autoimmune thyroiditis were receiving re-
placement therapy with thyroxine, and the patients with cancer
were receiving thyroxine as suppressive therapy. Patients with oth-
er serious medical illnesses were excluded.
Thirty-five patients were enrolled, and 33 completed the study:
31 women and 2 men, with a mean (±SD) age of 46±13 years
(Table 1). Sixteen patients had chronic autoimmune thyroiditis,
and 17 had thyroid cancer. The mean dose of thyroxine at base
line was 175±53 µg per day; the range was from 100 µg per day
(five patients) to 300 µg per day (two patients). The mean dura-
tion of treatment was 73±72 months. In all patients the dosage
had been stable for at least three months. The mean score on the
Hamilton Rating Scale for Depression (the 21-item “long” ver-
sion) was 9.8±5.4, on a scale from 0 (indicating no depression)




 Four women had major




One patient withdrew from the study because she became preg-
nant, and another because of anxiety. The study was approved by
the institutional review board of Kaunas Medical University, and




Patients took their usual dose of thyroxine through the first day
of the study. On this day each patient was assigned, according to
a prearranged randomization schedule, either to receive thyroxine
alone for five weeks, then thyroxine plus triiodothyronine for five
weeks, or to receive thyroxine plus triiodothyronine for five
weeks, then thyroxine alone for five weeks. The thyroxine (Berlin-
Chemie, Berlin, Germany) was given as 50-µg tablets at each pa-
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tient’s usual total dose, but 50 µg of the dose of thyroxine was
replaced by a capsule. These capsules contained either 50 µg of
thyroxine or 12.5 µg of triiodothyronine (Berlin-Chemie), de-
pending on the assigned treatment. They were prepared by a
pharmacist and were identical in appearance. If, for example, a pa-
tient had been treated with 200 µg of thyroxine per day, he or
she was instructed to take 150 µg of the usual thyroxine tablets
plus one capsule each morning. If the patient had been assigned
to receive thyroxine alone, the capsule contained 50 µg of thy-
roxine; if the patient had been assigned to receive thyroxine plus
triiodothyronine, the capsule contained 12.5 µg of triiodothyro-
nine. Patients took the medications once daily, half an hour be-
fore breakfast.
At the end of each five-week period, the patients were given an-
other batch of tablets and capsules. Only the pharmacist knew
which capsules had been dispensed. At the end of each treatment
phase, all patients, when asked, said that they had taken their




The patients were systematically studied on the last day of each
five-week treatment period. They reported to the clinic at about
9 a.m., having omitted breakfast but having taken their thyroid hor-
mone about two hours earlier. Venous blood was taken for meas-
urements of serum thyrotropin, thyroid hormones, cholesterol,





were performed. Assessments were made of cognitive function
and psychological state. Each patient had the same examiner for
whatever variable was being measured at each session, and the ex-




Serum samples were frozen, allowing the samples from all the
patients to be analyzed at the same time for each variable. Serum
thyrotropin was measured by immunoradiometric assay with kits
obtained from Orion Diagnostica (Espoo, Finland), with a sensitiv-
ity of 0.05 µU per milliliter. Serum free and total thyroxine and
triiodothyronine were measured with radioimmunoassay kits (Ori-
on Diagnostica). Serum total cholesterol and triglycerides were
measured by enzymatic colorimetric methods (Sera-Pak Choles-
terol Fast Color kit and Sera-Pak Triglycerides Fast Color kit,
Bayer, Tarrytown, N.Y.). Serum sex hormone–binding globulin
was measured with immunoenzymometric assay kits (Medix Bio-
chemica, Kauniainen, Finland). The intraassay variation ranged






The pulse rate was recorded after the patient had been supine
for five minutes. Blood pressure was measured in the sitting po-
sition. Electrocardiography was performed at both sessions, and




The sensory threshold (minimal detectable intensity of vibra-
tion) was measured with a biothesiometer (Model PVD, Biomedi-
cal, Newbury, Ohio) applied to the tip of the fourth finger and




 The Achilles tendon reflex was meas-







Psychological assessment was performed according to the 
 
Di-







 Symptoms were recorded according to the
Structured Clinical Interview of the DSM-III-R for assessment of


















 In the Digit
Symbol Test, a key is provided that pairs each of the numbers
1 through 9 with a nonsense symbol. Below are rows of pairs of
squares, the upper of which contains a number, the lower of
which is blank. With the key available, the subject is allowed 90
seconds to complete each pair of squares by entering the appro-
priate symbol. The raw score is the number of correct entries
completed in 90 seconds or until completion of the third row,
whichever occurs first. This score measures psychomotor per-
formance. With the key unavailable, the subject is then asked to
recall which symbol matched each number. The number of pairs
correctly recalled is a measure of incidental learning. Then the
subject copies 70 symbols. The less time is required for comple-
tion, the greater the subject’s psychomotor speed.
The first part of the Digit Span Test requires the subject to re-
peat spoken numbers with increasing numbers of digits; it measures
immediate auditory attention. The second part, which requires
the subject to repeat the numbers in reverse order, measures men-
tal flexibility.
The Visual Scanning Test assesses distractibility and visual in-
attentiveness. The subject is shown a “target” symbol and then
presented with a paper with a matrix of symbols containing 60
targets. The patient circles all the target symbols that he or she
can find. The time needed to complete the test, omissions, and
errors are scored.





 was used to assess the severity of depressive symptoms. Clin-
ically important depression is associated with scores of 20 or more.









*Plus–minus values are means ±SD.
†To convert values for serum free thyroxine to picomoles per liter, mul-
tiply by 12.87.






§Current depression was determined with use of the Structured Clinical
Interview in the 
 






























































































Age (yr) 45±10 48±15 46±13











Prestudy dose of thyroxine
(µg/day)
181±56 169±51 175±53
Duration of therapy (mo) 54±41 92±96 73±72
Serum thyrotropin (µU/ml) 0.3±0.8 1.5±1.8 0.7±1.4




Serum free thyroxine (ng/dl)† 2.0±0.7 1.9±0.5 2.0±0.6
Hamilton depression score‡ 10.0±5.5 9.5±5.3 9.8±5.4
Current depression (no. of 
patients)§
2 2 4
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 The Beck Depression Inventory
is a self-rating scale of 21 items, in which scores of 10 or less in-
dicate normal mood variation and scores of 11 or more reflect in-
creasing degrees of depression. The Spielberger State–Trait Anx-
iety Inventory is a self-rating scale consisting of 20 items; scores
below 50 are normal. The Profile of Mood States assesses affec-
tive states. The subject rates 65 items, each pertaining to an as-
pect of subjective state, on a scale from 0 to 4. When the scores
for combinations of items are added, values for six aspects of
mood and a global score are obtained.
Fifteen visual-analogue scales provided more detailed ratings of
mood and physical symptoms by the patients. Each scale consist-
ed of a pair of phrases, such as “as sad as possible” and “as happy
as possible,” at either end of a 100-mm line. The patient placed
a mark at the point best corresponding to his or her state at that
time. Measurement of the marks from the beginning of the line
generated a score.
At the completion of the study, each patient was asked which




Paired t-tests were used to compare paired data from the two
treatment periods. Nonpaired t-tests were used to compare values
in subgroups of patients — for example, depressed and nonde-
pressed patients. Results pertaining to the patients’ treatment
preferences were evaluated with use of McNemar’s test. Probabil-




The patients’ biochemical and physiologic values
after each treatment period are shown in Table 2. As
expected, the mean serum free and total thyroxine
concentrations were lower and the mean serum total
triiodothyronine concentration was higher after treat-
ment with thyroxine plus triiodothyronine than after
treatment with thyroxine alone. The mean serum thy-
rotropin concentrations were similar after the two
treatments. The mean serum cholesterol and triglyc-
eride concentrations also were similar after the two
treatments, whereas the mean serum sex hormone–
binding globulin concentration was significantly high-
er after treatment with thyroxine plus triiodothyro-
nine, suggesting that thyroid hormone action was
greater after treatment with thyroxine plus triiodo-
thyronine. The mean pulse rate at rest was slightly
higher after treatment with thyroxine plus triiodothy-
ronine, but mean blood-pressure values and neuro-
physiologic findings were similar after the two treat-
ments.
Scores pertaining to cognitive functioning and
mood were within normal limits, except that patients
were marginally less able to recall digit–symbol pairs
correctly on the Digit Symbol Test after treatment
with thyroxine alone (Table 3). Among the 17 com-
parisons, 6 pairs showed an advantage (P<0.05) for
treatment with thyroxine plus triiodothyronine and
none for treatment with thyroxine alone.
 
*Plus–minus values are means ±SD.
†To convert values for serum free and total thyroxine to picomoles per liter and nanomoles per
liter, respectively, multiply by 12.87. To convert values for serum triiodothyronine to nanomoles per
liter, multiply by 0.015. To convert values for triglycerides to millimoles per liter, multiply by
0.01129. To convert values for cholesterol to millimoles per liter, multiply by 0.02586.
































































































Serum thyrotropin (µU/ml) 0.8±2.5 0.5±1.1 0.56 0.3–5.0
No. of patients with undetectable serum 
thyrotropin (<0.05 µU/ml)
7 5 — —
Serum free thyroxine (ng/dl) 2.3±0.7 1.8±0.6 <0.001 0.7–2.1
Serum total thyroxine (µg/dl) 15.2±3.8 11.3±3.3 <0.001 4–11
Serum total triiodothyronine (ng/dl) 87±38 117±42 <0.001 75–175
Serum triglycerides (mg/dl) 129±54 132±55 0.76 47–228
Serum cholesterol (mg/dl) 219±46 217±43 0.66 152–268
Serum sex hormone–binding globulin 
(µg/dl)
2.6±1.3 3.1±1.5 0.007 0.4–3.5
Pulse rate at rest (beats/min) 69±11 72±12 0.04 —






















Achilles reflex relaxation half-time (msec) 282±22 286±28 0.28 240–320
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treatment was significantly better (P<0.05) on parts
of two of the three tests of cognitive performance
(Table 3). The higher scores for recall of pairs on the
Digit Symbol Test indicated better incidental learn-
ing, and the higher scores for recalling digits in re-
verse order on the Digit Span Test indicated im-
proved mental flexibility and attention.
The three self-rating mood scales pertained to de-
pression, anxiety, or both. After thyroxine-plus-tri-
iodothyronine treatment, the patients tended to be
less depressed (shown by lower scores on the Beck
Depression Inventory), and their global scores and
scores on the three subscales (fatigue–inertia, depres-
sion–dejection, and anger–hostility) of the Profile
of Mood States were significantly lower (P<0.05),
indicating improvement, than scores after treatment
with thyroxine alone (Table 3).
Eight visual-analogue scales pertained to mood
and seven to physical symptoms (Table 4). Patients
scored their mood as significantly better after thyrox-
ine-plus-triiodothyronine treatment on seven of the
eight mood scales (P<0.04) and scored their physi-
cal symptoms as significantly improved on three of
seven scales (P<0.02). Patients reported only slight
physical problems at both evaluations. Their mean
visual-analogue scores were closer to “no symptoms”
than to “severe symptoms” — that is, less than 50,
the middle of each test line.
When asked at the end of the study whether they
preferred the first or second treatment, 20 patients
preferred thyroxine plus triiodothyronine, 11 had
no preference, and 2 preferred thyroxine alone (P=
0.001). The order of treatment was unrelated to
preference. The two patients who preferred thyrox-
ine had noticed that they felt slightly “nervous” dur-
ing combined treatment. The 20 patients who pre-
ferred thyroxine plus triiodothyronine had noticed
that they were more energetic, had better concentra-
tion, and simply felt better. One woman became
anxious during treatment with thyroxine plus tri-
iodothyronine and was withdrawn from the study.
The order of treatment did not affect the results.
To determine whether triiodothyronine was more
beneficial in patients receiving either high ratios of
triiodothyronine to thyroxine (i.e., those who re-
ceived lower doses of thyroxine at base line) or low
ratios, we compared the results from the 20 patients
who were taking 100 to 150 µg of thyroxine at base
line with those from the 13 patients who were tak-
ing 200 to 300 µg. The results were similar in the
two groups. There was also no difference between
 
*Among the 17 tests, patients had better results after treatment with thyroxine plus triiodothyro-
nine on 14; 6 of these differences were significant (P<0.05). On two tests performance was better
after thyroxine treatment; neither difference was significant. Forward recall of digits was essentially
the same after both treatments. Plus–minus values are means ±SD.


















































































































Backward recall of digits




























Beck Depression Inventory 9.8±7.7 7.9±5.3 0.10 <11
Spielberger State–Trait Anxiety Inventory 44±11 45±8 0.38 <50
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the responses of the 4 patients with depression and
those of the 29 patients without depression. Finally,
the advantage of thyroxine plus triiodothyronine was
not limited to only a few patients. Analysis of the
psychological variables for which combined therapy
was most beneficial (Tables 3 and 4) showed that
most patients derived at least some benefit from the




Patients with hypothyroidism benefited when
12.5 µg of triiodothyronine was substituted for 50
µg of thyroxine in their treatment regimens. They
performed better on standard neuropsychological
tasks, and their psychological state improved. The
differences in most physiologic variables were slight,
but in any case, these are insensitive indicators of
thyroid hormone actions. Pulse rates and serum sex
hormone–binding globulin concentrations were high-
er after treatment with thyroxine plus triiodothyro-





 Serum thyroxine concentrations were lower
and triiodothyronine concentrations were higher af-
ter treatment with thyroxine plus triiodothyronine,
but serum thyrotropin concentrations, a sensitive
measure of thyroid hormone action, were similar af-
ter the two treatments. The apparent difference in
physiologic responses could reflect differences in tis-
sue uptake of the hormones, in the conversion of





The variables related to mental function for which
the substitution of triiodothyronine resulted in ben-
efit require fuller description. On tests of cognitive
performance and self-rating scales for mood, pa-
tients scored in the normal range on 16 of 17 meas-
ures after both treatments (Table 3), but on 6 of the
tests or scales they performed or felt significantly
better after receiving thyroxine plus triiodothyro-
nine. These results were reinforced by results on the
visual-analogue scales. No test result was better after
treatment with thyroxine alone. It seems clear that
treatment with thyroxine plus triiodothyronine im-
proved the quality of life for most patients. We think
that five weeks was probably long enough for the
maximal effect of the treatments to be detected, but
we cannot be sure.
Despite these results, it is clear that the substitu-
tion of triiodothyronine for a portion of regular thy-
roxine therapy is not sufficient treatment for depres-
sion, because the 4 depressed patients benefited from
triiodothyronine substitution no more than the other
29 patients. Nevertheless, in depressed patients who
have normal thyroid hormone concentrations, the
addition of triiodothyronine to standard antidepres-




This study extends two others in which different
regimens of thyroxine and triiodothyronine were com-
pared. In one study, in which the doses were much
higher than those used in this study, the patients





 In the other, an open trial involving nine
depressed patients who were receiving thyroxine-
replacement therapy but were responding poorly to
an antidepressant drug, the addition of triiodothyro-
nine (15 to 50 µg daily) to thyroxine (rather than
the substitution of triiodothyronine) resulted in a




There are at least two ways in which the use of
thyroxine alone for replacement therapy might de-
prive the brain of triiodothyronine. First, delivery of
triiodothyronine through the circulation, the source





 is deficient to the extent that thyroid
glandular secretion is deficient unless compensated
for by production in peripheral tissues. Second, cir-
culating thyroxine, and presumably thyroxine in the
brain, will be increased, and in the brain thyroxine





 However, the two hormones are differently
bound to plasma proteins and may be differently de-
livered to the brain.
 
22
The daily production of triiodothyronine by the
human thyroid gland is about 6 µg23; the rate of ab-
sorption of ingested triiodothyronine is almost 100
percent.24 Thus, the dose of triiodothyronine given
in the present study somewhat exceeded the normal
glandular production. The ideal replacement regi-
men when thyroid-gland function is absent or nearly
*On every scale, a lower score represents a more favorable
state. Scores of 0 or 100 are theoretically possible but are
rarely encountered. Plus–minus values are means ±SD.
†P values were calculated by paired t-tests.
TABLE 4. RESULTS ON VISUAL-ANALOGUE SCALES 
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absent might consist of 10 µg of triiodothyronine
daily in sustained-release form (because the hormone
is rapidly absorbed and metabolized), along with
enough thyroxine to ensure euthyroidism.
We conclude that in patients with hypothyroid-
ism, partial substitution of triiodothyronine for thy-
roxine may have more salutary effects on the brain
and perhaps other tissues than those of an equiva-
lent amount of thyroxine, as determined by their ef-
fects on thyrotropin secretion. This finding suggests
that thyroidal secretion of triiodothyronine is physi-
ologically important.
We are indebted to Susan Silva, Ph.D., for her advice regarding
the choice of psychometric tests and statistical methods, to Mr. Robert
Ekstrom for statistical assistance, and to Berlin-Chemie (Berlin,
Germany) for the supplies of thyroxine and triiodothyronine.
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